Amgen's AMG 416 trial for SHPT treatment meets primary and secondary endpoints

US-based biopharmaceutical firm Amgen has reported positive results from its second placebo-controlled phase three trial of AMG 416 to treat secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news